Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.
作者信息
Epstein Murray, Pecoits-Filho Roberto, Clase Catherine M, Sood Manish M, Kovesdy Csaba P
机构信息
Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, Florida.
Arbor Research Collaborative for Health, Ann Arbor, Michigan.
出版信息
Clin J Am Soc Nephrol. 2022 Mar;17(3):455-457. doi: 10.2215/CJN.13541021. Epub 2021 Dec 1.
Abstract
摘要
相似文献
1
Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.
Clin J Am Soc Nephrol. 2022 Mar;17(3):455-457. doi: 10.2215/CJN.13541021. Epub 2021 Dec 1.
2
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Eur J Intern Med. 2014 Feb;25(2):173-6. doi: 10.1016/j.ejim.2013.11.007. Epub 2013 Dec 4.
3
Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
Nephron Clin Pract. 2014;128(3-4):381-6. doi: 10.1159/000369138. Epub 2015 Jan 6.
4
Mineralcorticoid receptor blockers in chronic kidney disease.
Nefrologia (Engl Ed). 2021 May-Jun;41(3):258-275. doi: 10.1016/j.nefroe.2021.08.001. Epub 2021 Sep 1.
5
Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
BMJ Open. 2022 Feb 21;12(2):e057503. doi: 10.1136/bmjopen-2021-057503.
6
Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
Cardiorenal Med. 2020;10(1):32-41. doi: 10.1159/000503223. Epub 2019 Oct 30.
7
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Am J Nephrol. 2009;30(5):418-24. doi: 10.1159/000237742. Epub 2009 Sep 9.
8
Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
Am J Nephrol. 2018;48(3):172-180. doi: 10.1159/000492622. Epub 2018 Sep 3.
9
Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
Cardiorenal Med. 2024;14(1):191-201. doi: 10.1159/000538389. Epub 2024 Mar 21.
10
Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
J Med Assoc Thai. 2013 Aug;96(8):905-10.
引用本文的文献
1
Drug Development in Pediatric Chronic Kidney Disease: A Review of Promising Treatments, Old Challenges, and New Strategies.
Paediatr Drugs. 2025 May;27(3):283-291. doi: 10.1007/s40272-025-00684-8. Epub 2025 Feb 10.
2
Cardiovascular Efficacy and Safety of Finerenone: A Meta-Analysis of Randomized Controlled Trials.
Clin Cardiol. 2025 Feb;48(2):e70065. doi: 10.1002/clc.70065.
3
Hyperkalemia Incidence in Patients With Non-Dialysis Chronic Kidney Disease: A Large Retrospective Cohort Study From United States Clinical Care.
Kidney Med. 2024 Jul 25;6(10):100879. doi: 10.1016/j.xkme.2024.100879. eCollection 2024 Oct.
4
Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.
Kidney Med. 2023 Nov 27;6(1):100757. doi: 10.1016/j.xkme.2023.100757. eCollection 2024 Jan.
5
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives.
Biomedicines. 2023 Sep 9;11(9):2498. doi: 10.3390/biomedicines11092498.
6
Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.
ESC Heart Fail. 2023 Apr;10(2):1066-1076. doi: 10.1002/ehf2.14268. Epub 2022 Dec 23.
7
Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Front Pharmacol. 2022 Feb 7;13:819327. doi: 10.3389/fphar.2022.819327. eCollection 2022.
本文引用的文献
1
The RALES Legacy and Finerenone Use on CKD Patients.
Clin J Am Soc Nephrol. 2021 Sep;16(9):1432-1434. doi: 10.2215/CJN.02150221. Epub 2021 Aug 6.
2
Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.
Clin J Am Soc Nephrol. 2021 Mar 8;16(3):365-373. doi: 10.2215/CJN.12990820. Epub 2021 Feb 19.
3
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
4
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney Int. 2020 Jan;97(1):42-61. doi: 10.1016/j.kint.2019.09.018. Epub 2019 Oct 10.
5
Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena.
Kidney Int Suppl (2011). 2016 Apr;6(1):20-28. doi: 10.1016/j.kisu.2016.01.004. Epub 2016 Mar 14.
6
Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.
Am J Manag Care. 2015 Sep;21(11 Suppl):S212-20.
7
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Eur Heart J. 2013 Aug;34(31):2453-63. doi: 10.1093/eurheartj/eht187. Epub 2013 May 27.
8
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
N Engl J Med. 2004 Aug 5;351(6):543-51. doi: 10.1056/NEJMoa040135.
Zotero 插件